Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing

Glenview Capital increased its Teva Pharmaceutical stake by 868,457 shares in Q3, adding roughly $71.98m and bringing its position to 16,692,680 shares valued at $337.19m as of Sept. 30, 2025 — equivalent to 7.51% of its 13F AUM and the fund’s fourth-largest holding. The build comes as Teva shares have rallied about 63.5% over the past year to $28.46 (Dec. 5, 2025); the company has a market cap near $29.2bn, TTM revenue of $16.88bn and net income of $666.7m. For institutional investors, the purchase signals elevated conviction from a sizable healthcare-focused hedge fund and increases Teva’s importance to Glenview’s portfolio, with potential implications for liquidity, trading flows and shareholder influence if the position changes further.

Analysis

Glenview Capital Management increased its stake in Teva Pharmaceutical (NYSE: TEVA) by 868,457 shares in Q3, adding roughly $71.98 million and bringing its post-trade position to 16,692,680 shares valued at $337.19 million as of September 30, 2025, per an SEC filing dated November 14, 2025. That holding represents 7.51% of Glenview’s 13F-disclosed AUM and is now the fund’s fourth-largest position behind CVS, THC, and GPN. The filing notes the position value rose both from additional share accumulation and price appreciation.

Teva shares traded at $28.46 on December 5, 2025, up 63.5% over the prior year and outperforming the S&P 500 by 49.6 percentage points; the company reports a market capitalization of $29.15 billion, TTM revenue of $16.88 billion and TTM net income of $666.71 million. Glenview’s added exposure and the stock’s strong one- and five-year performance (five-year gain cited at +157%) signal a bullish institutional view while underscoring momentum-driven returns to date.

The escalation in Glenview’s weighting creates both positive catalysts and risks: it increases the potential for meaningful buying or selling flows and raises concentration risk within the fund’s portfolio. Investors should note 13F filings are lagged and use this disclosure as a signal to verify current prices, monitor subsequent filings for further activity, and reassess position sizing against Teva’s fundamentals and recent run-up.

Key Decisions for Investors

• Treat Glenview’s additional $72 million purchase as a bullish institutional signal but verify current Teva price and position before trading given the lag in 13F filings
• Consider incremental exposure to TEVA only after sizing positions to account for concentration risk (Glenview’s stake equals 7.51% of its 13F AUM) and the stock’s 63.5% one-year run-up
• Monitor upcoming 13F/13D activity, Glenview commentary or activism indicators and Teva’s quarterly fundamentals (revenue and net income trends) as potential catalysts for further upside or downside
• Use protective risk management (stop-losses or hedges) if adding exposure, since recent price appreciation increases the risk of mean reversion or volatility driven by large institutional flows